A drug commonly used to treat arthritis sufferers may also be effective in tackling dry age-related macular degeneration (AMD), a new report has claimed.
Although there are several medications for patients with vision-threatening wet AMD there are no effective treatments for advanced dry AMD, but this may soon change.
That is according to a research group led by Dr Jason Slakter at the New York University School of Medicine, who has tested the effects of fenretinide, a synthetic derivative of vitamin A.
He noted that the risk of developing wet AMD decreased almost two-fold in dry AMD patients who took the medication
"Evidence from our study and others points to fenretinide"s potential to treat and prevent diseases of the retina," Dr Slakter noted.
According to a recent report in an issue of the Archives of Ophthalmology, the last decade has seen "substantial changes" in the treatment options available, particularly in the care of neovascular AMD.
by Adrian Galbreth